BioTherapeutics | 1800 Kraft Dr., Suite 200, Blacksburg, VA, 24060

The next frontier in precision medicine and health innovation for preventing and treating inflammation and metabolic disease.

Abscisic Acid Receives GRAS Approval
BLACKSBURG, Va., October 21, 2016 – Abscisic acid (ABA) has received Generally Recognized as Safe (GRAS) classification from an expert panel with expertise in toxicology, natural products...
News / October 21 2016
Senator Edwards Visits BioTherapeutics
BLACKSBURG, VA., October 17, 2016—Senator John Edwards visited BioTherapeutics Inc. (BTI) on Thursday October 6, 2016 to tour their facility at the VT Corporate Research Center and learn...
News / October 16 2016
TEDx Virginia Tech: Accelerated Path to Cures
BLACKSBURG, VA., October 7, 2016 – This is the fifth year of the TEDx series at Virginia Tech. Featured speakers will focus their talks upon the theme of “Spark,” as in the moment of...
News / October 07 2016

Our Purpose

Biotherapeutics Inc. (BTI) is a science-based biotechnology company that integrates Nutritionals, Therapeutics and IT to advance interventions for preventing and treating autoimmune and metabolic diseases.

See more about us
BioTherapeutics Awarded New NIH Grant To Develop Medical Foods for Glycemic Control
BLACKSBURG, VA., Sept. 1, 2016 – BioTherapeutics, Inc. (BTI)—a biotech company that develops nutritionals for digestive health, immune health, and glycemic control—announced today...
News / September 01 2016
Pervida Brand Launches Media Campaign to Support Crowdfunding
BLACKSBURG, VA: Aug 19, 2016—Today, Blacksburg-based nutritional brand Pervida™ launched a media campaign in support of crowdfunding efforts. With articles in Roanoke Times and...
News / August 21 2016
Dr. William Sandborn Joins SAB
BLACKSBURG, VA: July 18, 2016—William J. Sandborn, MD—Chief, Division of Gastroenterology at University of California San Diego School of Medicine—has recently joined the...
News / July 19 2016
Precision Medicine and Health at BioTherapeutics
BLACKSBURG, VA: June 24, 2016 – Diabetes. Inflammatory Bowel Disease (IBD). Clostridium difficile-associated disease. These and a host of other diseases and syndromes have become...
News / June 24 2016
PERVIDA™—A Brand For a Healthy Lifestyle
BLACKSBURG, VA: June 11, 2016—What if you could drink your way to health? What if vending machines stocked with fortified waters could help maintain healthy blood sugar levels,...
News / June 11 2016

Now Hiring

Interested in becoming a part of the BTI team? Take a look at our job openings

View all positions
Abscisic acid: The Missing Hormone for Blood-Sugar Control Presented at ADA
NEW ORLEANS, LA: June 10, 2016— Diabetes affects nearly 30 million children and adults in the United States. More than 230,000 Americans die each year from complications of the...
News / June 10 2016
Toxicology Experiments Demonstrate that BT-11 has a Benign Safety Profile
BLACKSBURG, VA: May 31, 2016 – BTI Pharmaceuticals’ program lead for inflammatory bowel disease (IBD)—BT-11—has demonstrated an outstanding therapeutic efficacy in 3 validated mouse...
News / May 31 2016
BioTherapeutics Expands Scientific Advisory Board
BLACKSBURG, VA: May 28, 2016—Jean-Frederic Colombel, MD, an internationally renowned clinician and researcher in inflammatory bowel disease (IBD) and gastroenterology, has been appointed...
News / May 29 2016


NIMML uses innovation to tackle challenges in infectious, immune-mediated, and chronic inflammatory disease research. BTI was founded in 2008 by Dr. Josep Bassaganya-Riera as a result of the technology developed at VT’s Nutritional Immunology and Molecular Medicine Laboratory (NIMML).

Go to NIMML Website